Sight Sciences (SGHT) Earnings Date & Reports

Key Takeaways

• Sight Sciences reported record total revenue of $24.9 million for the third quarter of 2026, up 25% year over year from $19.9 million.
• Interventional Glaucoma (IG) revenue grew 7% to $21.0 million, while Interventional Dry Eye (IDE) revenue hit a record $3.9 million, up 45% sequentially.
• Net loss narrowed to $6.8 million, or $0.12 per share, an improvement from $8.2 million, or $0.16 per share, a year earlier.
• Management raised full-year 2026 revenue guidance to $92 million–$93 million, up from the prior range of $88 million–$92 million.
• Cash usage fell sharply to $2.4 million in the quarter, down 74% year over year, strengthening the path toward cash-flow breakeven.
• For more on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Discover Trending AI Robots for AI-driven trading insights.

Earnings Context and Why It Matters

Sight Sciences is an eyecare technology company developing minimally invasive, interventional solutions for two of the world's most prevalent eye conditions: glaucoma and dry eye disease. Its third-quarter 2026 results matter because they test whether the company can sustain double-digit revenue growth while simultaneously narrowing losses and reducing cash burn. The quarter also marked the commercial launch of its next-generation OMNI Ultra system and followed a U.S. Food and Drug Administration (FDA) label expansion for its TearCare technology, making this report a key checkpoint on both product momentum and the company's path toward profitability.

Reported Results

Sight Sciences reported record revenue of $24.9 million for the third quarter ended September 30, 2026, a 25% increase from $19.9 million in the prior-year period. The result exceeded consensus expectations of roughly $23.5 million.

Interventional Glaucoma (IG) revenue reached $21.0 million, up 7% year over year, marking a fifth consecutive quarter of growth. Interventional Dry Eye (IDE) revenue climbed to a record $3.9 million, compared with just $0.2 million a year earlier and a 45% sequential increase from $2.7 million in the second quarter.

Gross margin held at 86%, in line with the prior year, while IDE gross margin improved to 79% from 38% a year ago, driven by higher average selling prices. Total operating expenses rose 10% to $27.5 million.

The company posted a net loss of $6.8 million, or $0.12 per share, an improvement from $8.2 million, or $0.16 per share, a year earlier. The loss per share was in line with consensus estimates.

Management raised full-year 2026 revenue guidance to $92 million–$93 million, representing 19%–20% growth, up from $88 million–$92 million previously. IG revenue is now expected at $80 million–$81 million and IDE revenue at approximately $12 million. Adjusted operating expense guidance was maintained at $92 million–$94 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Sight Sciences, the AI Screener offers a structured way to surface actionable ideas across the broader healthcare and medical-device landscape.

Market Reaction and Investor Sentiment

Investor sentiment heading into the print focused on whether Sight Sciences could extend its streak of double-digit growth while demonstrating continued progress toward cash-flow breakeven. The record revenue, the 74% reduction in cash usage, and the upward revision to full-year guidance all addressed those core concerns, suggesting a broadly constructive read on the quarter.

The IDE segment was a particular focal point, given its rapid sequential acceleration and the FDA label expansion for TearCare. Management's commentary around payer coverage expansion—including additional OMNI and SION coverage through Aetna adding approximately 25 million covered lives—reinforced the view that market access is broadening. Key risk factors that investors continue to weigh include the company's ongoing net losses, the early-stage nature of the dry eye opportunity, and competitive dynamics in interventional glaucoma.

Forward Outlook and Key Factors to Monitor

Following this report, the central theme for investors is whether Sight Sciences can translate its revenue momentum into a sustainable path toward profitability without additional equity financing. Management reiterated that it remains well positioned to reach cash-flow breakeven, and the sharp improvement in cash usage supports that narrative.

The full commercial launch of OMNI Ultra will be a key near-term catalyst. As the next-generation iteration of the company's flagship glaucoma platform, its adoption among surgeons will be closely watched as an indicator of future IG growth. Early user feedback cited by management has been positive, but the coming quarters will test whether that enthusiasm converts into durable utilization.

The IDE business is another important swing factor. With full-year IDE revenue now guided to approximately $12 million—up sharply from $1.6 million in 2025—the pace of TearCare adoption and any additional payer coverage decisions will be critical. Management has indicated it anticipates fee schedules and coverage policies in the coming quarters.

Finally, investors should monitor operating expense discipline. While adjusted operating expense guidance was maintained, the company continues to invest in scaling the IDE business. The balance between growth investment and narrowing losses will shape how the market evaluates the company's margin trajectory in subsequent quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations